Chemistry:Filaminast
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C15H20N2O4 |
| Molar mass | 292.335 g·mol−1 |
| 3D model (JSmol) | |
| |
Filaminast (code name WAY-PDA 641)[1] was a drug candidate developed by Wyeth-Ayerst.[2]:Table 2 It is a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts.[3][4]:668, 678 It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.[4]:678
See also
References
- ↑ "Filaminist entry". Pubchem. https://pubchem.ncbi.nlm.nih.gov/compound/9578243?from=summary#section=Top.
- ↑ "ABCD of the phosphodiesterase family: interaction and differential activity in COPD". International Journal of Chronic Obstructive Pulmonary Disease 3 (4): 543–61. 2008. doi:10.2147/COPD.S1761. PMID 19281073.
- ↑ "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology 155 (3): 288–90. October 2008. doi:10.1038/bjp.2008.297. PMID 18660832.
- ↑ 4.0 4.1 "Medicinal Chemistry of PDE4 Inhibitors. Chapter 33". Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press. 5 December 2006. ISBN 978-1-4200-2084-7.
 |  |
